2023 Q4 Form 10-Q Financial Statement
#000095017023060303 Filed on November 07, 2023
Income Statement
Concept | 2023 Q4 | 2023 Q3 |
---|---|---|
Revenue | $18.75M | $20.01M |
YoY Change | -8.72% | 7.13% |
Cost Of Revenue | $2.776M | $2.677M |
YoY Change | -24.26% | -8.57% |
Gross Profit | $15.98M | $17.33M |
YoY Change | -5.35% | 10.05% |
Gross Profit Margin | 85.2% | 86.62% |
Selling, General & Admin | $23.66M | $26.50M |
YoY Change | -17.56% | -15.97% |
% of Gross Profit | 148.09% | 152.92% |
Research & Development | $3.427M | $4.239M |
YoY Change | -34.51% | -29.97% |
% of Gross Profit | 21.45% | 24.46% |
Depreciation & Amortization | $159.0K | $200.0K |
YoY Change | 3.92% | 0.0% |
% of Gross Profit | 1.0% | 1.15% |
Operating Expenses | $27.09M | $30.74M |
YoY Change | -20.18% | -18.22% |
Operating Profit | -$11.11M | -$13.41M |
YoY Change | -34.85% | -38.61% |
Interest Expense | -$1.351M | $1.432M |
YoY Change | 10.47% | 26.61% |
% of Operating Profit | ||
Other Income/Expense, Net | $1.780M | $1.886M |
YoY Change | 29.08% | 146.21% |
Pretax Income | -$10.68M | -$12.96M |
YoY Change | -36.79% | -41.66% |
Income Tax | $10.00K | $78.00K |
% Of Pretax Income | ||
Net Earnings | -$10.69M | -$13.04M |
YoY Change | -36.77% | -41.36% |
Net Earnings / Revenue | -57.02% | -65.15% |
Basic Earnings Per Share | -$0.27 | |
Diluted Earnings Per Share | -$0.22 | -$0.27 |
COMMON SHARES | ||
Basic Shares Outstanding | 48.75M | 48.65M |
Diluted Shares Outstanding | 48.67M |
Balance Sheet
Concept | 2023 Q4 | 2023 Q3 |
---|---|---|
SHORT-TERM ASSETS | ||
Cash & Short-Term Investments | $138.1M | $144.5M |
YoY Change | -25.34% | -27.68% |
Cash & Equivalents | $138.1M | $144.5M |
Short-Term Investments | ||
Other Short-Term Assets | $2.604M | $2.900M |
YoY Change | -23.75% | -34.26% |
Inventory | $7.849M | $9.240M |
Prepaid Expenses | ||
Receivables | $14.29M | $16.92M |
Other Receivables | $0.00 | $0.00 |
Total Short-Term Assets | $162.9M | $173.6M |
YoY Change | -22.32% | -21.94% |
LONG-TERM ASSETS | ||
Property, Plant & Equipment | $3.098M | $1.556M |
YoY Change | 97.2% | -0.77% |
Goodwill | ||
YoY Change | ||
Intangibles | ||
YoY Change | ||
Long-Term Investments | ||
YoY Change | ||
Other Assets | $682.0K | $655.0K |
YoY Change | 223.22% | 224.26% |
Total Long-Term Assets | $3.780M | $3.082M |
YoY Change | 11.31% | 6.61% |
TOTAL ASSETS | ||
Total Short-Term Assets | $162.9M | $173.6M |
Total Long-Term Assets | $3.780M | $3.082M |
Total Assets | $166.7M | $176.6M |
YoY Change | -21.79% | -21.57% |
SHORT-TERM LIABILITIES | ||
YoY Change | ||
Accounts Payable | $1.731M | $3.535M |
YoY Change | -35.6% | 9.14% |
Accrued Expenses | $8.302M | $2.550M |
YoY Change | 56.43% | -41.38% |
Deferred Revenue | ||
YoY Change | ||
Short-Term Debt | $0.00 | $0.00 |
YoY Change | ||
Long-Term Debt Due | $2.219M | $0.00 |
YoY Change | ||
Total Short-Term Liabilities | $12.25M | $14.33M |
YoY Change | -31.23% | -17.57% |
LONG-TERM LIABILITIES | ||
Long-Term Debt | $31.71M | $33.77M |
YoY Change | -4.82% | 1.83% |
Other Long-Term Liabilities | $2.476M | $1.476M |
YoY Change | 32.62% | -15.71% |
Total Long-Term Liabilities | $34.18M | $35.24M |
YoY Change | -2.83% | 0.95% |
TOTAL LIABILITIES | ||
Total Short-Term Liabilities | $12.25M | $14.33M |
Total Long-Term Liabilities | $34.18M | $35.24M |
Total Liabilities | $46.44M | $49.57M |
YoY Change | -12.38% | -5.21% |
SHAREHOLDERS EQUITY | ||
Retained Earnings | -$294.8M | -$284.1M |
YoY Change | 23.24% | 27.8% |
Common Stock | $415.0M | $411.2M |
YoY Change | 3.93% | 4.02% |
Preferred Stock | ||
YoY Change | ||
Treasury Stock (at cost) | ||
YoY Change | ||
Treasury Stock Shares | ||
Shareholders Equity | $120.2M | $127.1M |
YoY Change | ||
Total Liabilities & Shareholders Equity | $166.7M | $176.6M |
YoY Change | -21.79% | -21.57% |
Cashflow Statement
Concept | 2023 Q4 | 2023 Q3 |
---|---|---|
OPERATING ACTIVITIES | ||
Net Income | -$10.69M | -$13.04M |
YoY Change | -36.77% | -41.36% |
Depreciation, Depletion And Amortization | $159.0K | $200.0K |
YoY Change | 3.92% | 0.0% |
Cash From Operating Activities | -$6.484M | -$9.830M |
YoY Change | -58.17% | -51.32% |
INVESTING ACTIVITIES | ||
Capital Expenditures | $264.0K | $310.0K |
YoY Change | 104.65% | -213.97% |
Acquisitions | ||
YoY Change | ||
Other Investing Activities | ||
YoY Change | ||
Cash From Investing Activities | -$264.0K | -$310.0K |
YoY Change | 104.65% | 13.97% |
FINANCING ACTIVITIES | ||
Cash Dividend Paid | ||
YoY Change | ||
Common Stock Issuance & Retirement, Net | ||
YoY Change | ||
Debt Paid & Issued, Net | ||
YoY Change | ||
Cash From Financing Activities | 376.0K | 120.0K |
YoY Change | -53.69% | -35.48% |
NET CHANGE | ||
Cash From Operating Activities | -6.484M | -9.830M |
Cash From Investing Activities | -264.0K | -310.0K |
Cash From Financing Activities | 376.0K | 120.0K |
Net Change In Cash | -6.372M | -10.02M |
YoY Change | -57.0% | -50.59% |
FREE CASH FLOW | ||
Cash From Operating Activities | -$6.484M | -$9.830M |
Capital Expenditures | $264.0K | $310.0K |
Free Cash Flow | -$6.748M | -$10.14M |
YoY Change | -56.83% | -49.1% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001531177 | ||
dei |
Amendment Flag
AmendmentFlag
|
false | ||
dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q3 | ||
CY2023Q3 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2022Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2023Q3 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | |
CY2022Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | |
sght |
Taxes Paid On The Net Share Settlement Of Restricted Stock Units
TaxesPaidOnTheNetShareSettlementOfRestrictedStockUnits
|
0 | ||
dei |
Document Type
DocumentType
|
10-Q | ||
CY2022Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
2688000 | |
CY2023Q3 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
5501000 | |
CY2022Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
7352000 | |
dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | ||
dei |
Document Period End Date
DocumentPeriodEndDate
|
2023-09-30 | ||
dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2023 | ||
dei |
Document Transition Report
DocumentTransitionReport
|
false | ||
dei |
Entity File Number
EntityFileNumber
|
001-40587 | ||
dei |
Entity Registrant Name
EntityRegistrantName
|
SIGHT SCIENCES, INC. | ||
dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | ||
dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
80-0625749 | ||
dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
4040 Campbell Ave | ||
dei |
Entity Address Address Line2
EntityAddressAddressLine2
|
Suite 100 | ||
dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Menlo Park | ||
dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
CA | ||
dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
94025 | ||
dei |
City Area Code
CityAreaCode
|
877 | ||
dei |
Local Phone Number
LocalPhoneNumber
|
266-1144 | ||
dei |
Security12b Title
Security12bTitle
|
Common Stock, par value $0.001 per share | ||
dei |
Trading Symbol
TradingSymbol
|
SGHT | ||
dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | ||
dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | ||
dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | ||
dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | ||
dei |
Entity Small Business
EntitySmallBusiness
|
true | ||
dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
true | ||
dei |
Entity Ex Transition Period
EntityExTransitionPeriod
|
false | ||
dei |
Entity Shell Company
EntityShellCompany
|
false | ||
CY2023Q4 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
48749876 | |
CY2023Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
144501000 | |
CY2022Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
185000000 | |
CY2023Q3 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
1405000 | |
CY2022Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
1024000 | |
CY2023Q3 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
16919000 | |
CY2022Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
15148000 | |
CY2023Q3 | us-gaap |
Inventory Net
InventoryNet
|
9240000 | |
CY2022Q4 | us-gaap |
Inventory Net
InventoryNet
|
6114000 | |
CY2023Q3 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
2899000 | |
CY2022Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
3415000 | |
CY2023Q3 | us-gaap |
Assets Current
AssetsCurrent
|
173559000 | |
CY2022Q4 | us-gaap |
Assets Current
AssetsCurrent
|
209677000 | |
CY2023Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1556000 | |
CY2022Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1571000 | |
CY2023Q3 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
871000 | |
CY2022Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
1614000 | |
CY2023Q3 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
655000 | |
CY2022Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
211000 | |
CY2023Q3 | us-gaap |
Assets
Assets
|
176641000 | |
CY2022Q4 | us-gaap |
Assets
Assets
|
213073000 | |
CY2023Q3 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
3535000 | |
CY2023Q3 | us-gaap |
Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
|
5295000 | |
CY2022Q4 | us-gaap |
Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
|
7777000 | |
CY2023Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
14331000 | |
CY2022Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
17817000 | |
CY2023Q3 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
33765000 | |
CY2022Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
33313000 | |
CY2023Q3 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
1476000 | |
CY2022Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
1867000 | |
CY2023Q3 | us-gaap |
Liabilities
Liabilities
|
49572000 | |
CY2022Q4 | us-gaap |
Liabilities
Liabilities
|
52997000 | |
CY2023Q3 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
CY2022Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
CY2023Q3 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
CY2022Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
CY2023Q3 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
CY2023Q3 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
CY2022Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
CY2022Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
CY2023Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2022Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2023Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | |
CY2022Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | |
CY2022Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
48722219 | |
CY2023Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
48722219 | |
CY2022Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
48298138 | |
CY2023Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
48298138 | |
CY2023Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
49000 | |
CY2022Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
48000 | |
CY2023Q3 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
411119000 | |
CY2022Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
399271000 | |
CY2023Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-284099000 | |
CY2022Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-239243000 | |
CY2023Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
127069000 | |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
160076000 | |
CY2023Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
176641000 | |
CY2022Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
213073000 | |
CY2023Q3 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
20009000 | |
CY2022Q3 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
18677000 | |
us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
62305000 | ||
us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
50788000 | ||
CY2023Q3 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
2677000 | |
CY2022Q3 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
2928000 | |
us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
9105000 | ||
us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
8696000 | ||
CY2023Q3 | us-gaap |
Gross Profit
GrossProfit
|
17332000 | |
CY2022Q3 | us-gaap |
Gross Profit
GrossProfit
|
15749000 | |
CY2023Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
48671049 | |
us-gaap |
Gross Profit
GrossProfit
|
53200000 | ||
us-gaap |
Gross Profit
GrossProfit
|
42092000 | ||
CY2023Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
4239000 | |
CY2022Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
6053000 | |
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
14129000 | ||
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
17626000 | ||
CY2023Q3 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
26504000 | |
CY2022Q3 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
31541000 | |
us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
85235000 | ||
us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
91367000 | ||
CY2023Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
30743000 | |
CY2022Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
37594000 | |
us-gaap |
Operating Expenses
OperatingExpenses
|
99364000 | ||
us-gaap |
Operating Expenses
OperatingExpenses
|
108993000 | ||
CY2023Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-13411000 | |
CY2022Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-21845000 | |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-46164000 | ||
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-66901000 | ||
CY2023Q3 | us-gaap |
Interest Expense
InterestExpense
|
1432000 | |
CY2022Q3 | us-gaap |
Interest Expense
InterestExpense
|
1131000 | |
us-gaap |
Interest Expense
InterestExpense
|
4057000 | ||
us-gaap |
Interest Expense
InterestExpense
|
3243000 | ||
CY2023Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
1886000 | |
CY2022Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
766000 | |
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
5465000 | ||
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
846000 | ||
CY2023Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-12957000 | |
CY2022Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-22210000 | |
us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-44756000 | ||
us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-69298000 | ||
CY2023Q3 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
78000 | |
CY2022Q3 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
19000 | |
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
100000 | ||
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
37000 | ||
CY2023Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-13035000 | |
CY2022Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-22229000 | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-44856000 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-69335000 | ||
CY2023Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.27 | |
CY2023Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.27 | |
CY2022Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.46 | |
CY2022Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.46 | |
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.92 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.92 | ||
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.45 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.45 | ||
CY2023Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
48671049 | |
CY2022Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
47910541 | |
CY2022Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
47910541 | |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
48538517 | ||
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
48538517 | ||
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
47728845 | ||
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
47728845 | ||
CY2023Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
136131000 | |
CY2023Q3 | sght |
Issuance Of Common Stock Upon Exercise Of Stock Options
IssuanceOfCommonStockUponExerciseOfStockOptions
|
117000 | |
CY2023Q3 | sght |
Issuance Of Common Stock Upon Vesting Of Restricted Stock Units
IssuanceOfCommonStockUponVestingOfRestrictedStockUnits
|
0 | |
CY2023Q3 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
3856000 | |
CY2023Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-13035000 | |
CY2023Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
127069000 | |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
160076000 | |
sght |
Issuance Of Common Stock Upon Exercise Of Stock Options
IssuanceOfCommonStockUponExerciseOfStockOptions
|
288000 | ||
sght |
Issuance Of Common Stock Upon Vesting Of Restricted Stock Units
IssuanceOfCommonStockUponVestingOfRestrictedStockUnits
|
1000 | ||
us-gaap |
Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
|
-222000 | ||
us-gaap |
Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
|
661000 | ||
us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
11121000 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-44856000 | ||
CY2023Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
127069000 | |
CY2022Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
191759000 | |
CY2022Q3 | sght |
Issuance Of Common Stock Upon Exercise Of Stock Options
IssuanceOfCommonStockUponExerciseOfStockOptions
|
186000 | |
CY2022Q3 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
3223000 | |
CY2022Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-22229000 | |
CY2022Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
172939000 | |
CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
232107000 | |
sght |
Issuance Of Common Stock Upon Exercise Of Stock Options
IssuanceOfCommonStockUponExerciseOfStockOptions
|
438000 | ||
us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
9729000 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-69335000 | ||
CY2022Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
172939000 | |
us-gaap |
Profit Loss
ProfitLoss
|
-44856000 | ||
us-gaap |
Profit Loss
ProfitLoss
|
-69335000 | ||
us-gaap |
Depreciation
Depreciation
|
455000 | ||
us-gaap |
Depreciation
Depreciation
|
557000 | ||
us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
452000 | ||
us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
502000 | ||
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
11121000 | ||
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
9729000 | ||
us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
416000 | ||
us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
395000 | ||
us-gaap |
Inventory Write Down
InventoryWriteDown
|
219000 | ||
us-gaap |
Inventory Write Down
InventoryWriteDown
|
124000 | ||
sght |
Noncash Operating Lease Cost
NoncashOperatingLeaseCost
|
743000 | ||
sght |
Noncash Operating Lease Cost
NoncashOperatingLeaseCost
|
374000 | ||
us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-66000 | ||
us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-55000 | ||
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
2187000 | ||
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
4280000 | ||
us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
3345000 | ||
us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
2169000 | ||
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-517000 | ||
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
245000 | ||
us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
444000 | ||
us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
0 | ||
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
841000 | ||
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-77000 | ||
us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
-1851000 | ||
us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
2006000 | ||
us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-3089000 | ||
us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
1631000 | ||
us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
242000 | ||
us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
270000 | ||
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-40700000 | ||
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-60463000 | ||
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
527000 | ||
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
841000 | ||
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-527000 | ||
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-841000 | ||
us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
289000 | ||
us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
436000 | ||
sght |
Taxes Paid On The Net Share Settlement Of Restricted Stock Units
TaxesPaidOnTheNetShareSettlementOfRestrictedStockUnits
|
-222000 | ||
us-gaap |
Proceeds From Repayment Of Loans By Employee Stock Ownership Plans
ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans
|
661000 | ||
us-gaap |
Proceeds From Repayment Of Loans By Employee Stock Ownership Plans
ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans
|
0 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
728000 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
436000 | ||
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-40499000 | ||
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-60868000 | ||
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
185000000 | |
CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
260687000 | |
CY2023Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
144501000 | |
CY2022Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
199819000 | |
us-gaap |
Interest Paid Net
InterestPaidNet
|
3167000 | ||
us-gaap |
Interest Paid Net
InterestPaidNet
|
2350000 | ||
us-gaap |
Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
|
81000 | ||
us-gaap |
Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
|
46000 | ||
us-gaap |
Nature Of Operations
NatureOfOperations
|
<p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 1. Company and Nature of Business</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Description of Business</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sight Sciences, Inc. (the “Company”) was incorporated in the State of Delaware in 2010 and is headquartered in Menlo Park, California. The Company is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company's product portfolio aligns with its two reportable operating segments: Surgical Glaucoma and Dry Eye. The products for the Surgical Glaucoma segment include the OMNI® Surgical System ("OMNI"), which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, the world's leading cause of irreversible blindness, and the SION Surgical Instrument ("SION"), a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare® System ("TearCare") for ophthalmologists and optometrists. TearCare is a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD) when used in conjunction with manual expression of the meibomian glands, enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease.</span></p><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Significant Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since inception, the Company has incurred losses and negative cash flows from operations. As of September 30, 2023, the Company had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">284.1</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and recorded a net loss of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">44.9</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the nine months then ended and expects to incur additional losses in the future. If the Company’s revenue levels from its products are not sufficient or if the Company is unable to secure additional funding when desired, the Company may need to delay the development of its products, scale back its business and operations, or change its business strategy.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company believes that its existing sources of liquidity will satisfy its working capital and capital requirements for at least 12 months from the issuance of its financial statements. Any failure to generate increased revenue, achieve improved gross margins, or control operating costs could require the Company to raise additional capital through equity or debt financing. Such additional financing may not be available on acceptable terms, or at all, and could require the Company to modify, delay, or abandon some of its planned future expansion or expenditures or reduce some of its ongoing operating costs, which could harm its business, operating results, financial condition, and ability to achieve its intended business objectives.</span></p> | ||
CY2023Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-284100000 | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-44900000 | ||
us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company's unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The most significant areas requiring the use of management estimates and assumptions relate to the provision for credit losses, inventory excess and obsolescence, the selection of useful lives of property and equipment, determination of the fair value of stock option grants, and provisions for income taxes and contingencies. Management evaluates its estimates and assumptions on an ongoing basis using historical experience, existing and known circumstances, authoritative accounting pronouncements, and other factors that management believes to be reasonable, including the current macroeconomic environment, and makes adjustments when facts and circumstances dictate. Although the full impact of these factors is unknown and cannot be reasonably estimated, the Company believes it has made appropriate accounting estimates and assumptions based on information available as of the date of the unaudited condensed consolidated financial statements. Actual results could differ from these estimates and such differences could be material to the Company’s financial position and results of operations.</span></p> | ||
CY2023Q3 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
3023000 | |
CY2022Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
3005000 | |
CY2023Q3 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
1467000 | |
CY2022Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
1434000 | |
CY2023Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1556000 | |
CY2022Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1571000 | |
CY2023Q3 | us-gaap |
Depreciation
Depreciation
|
200000 | |
CY2022Q3 | us-gaap |
Depreciation
Depreciation
|
200000 | |
us-gaap |
Depreciation
Depreciation
|
500000 | ||
us-gaap |
Depreciation
Depreciation
|
600000 | ||
CY2023Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
2550000 | |
CY2022Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
5307000 | |
CY2023Q3 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
910000 | |
CY2022Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
1033000 | |
CY2023Q3 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
376000 | |
CY2022Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
348000 | |
CY2023Q3 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
1459000 | |
CY2022Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
1087000 | |
CY2023Q3 | sght |
Accounts Payable And Other Accrued Liabilitie Current
AccountsPayableAndOtherAccruedLiabilitieCurrent
|
5295000 | |
CY2022Q4 | sght |
Accounts Payable And Other Accrued Liabilitie Current
AccountsPayableAndOtherAccruedLiabilitieCurrent
|
7775000 | |
CY2023Q3 | sght |
Interest Payable Non Current
InterestPayableNonCurrent
|
1437000 | |
CY2022Q4 | sght |
Interest Payable Non Current
InterestPayableNonCurrent
|
1194000 | |
CY2023Q3 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
0 | |
CY2022Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
635000 | |
CY2023Q3 | sght |
Other Non Current Liabilities
OtherNonCurrentLiabilities
|
39000 | |
CY2022Q4 | sght |
Other Non Current Liabilities
OtherNonCurrentLiabilities
|
38000 | |
CY2023Q3 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
1476000 | |
CY2022Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
1867000 | |
CY2023Q3 | us-gaap |
Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
|
35000000 | |
CY2022Q4 | us-gaap |
Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
|
35000000 | |
CY2023Q3 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
1235000 | |
CY2022Q4 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
1687000 | |
CY2023Q3 | us-gaap |
Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
|
33765000 | |
CY2022Q4 | us-gaap |
Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
|
33313000 | |
CY2023Q3 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
0 | |
CY2022Q4 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
0 | |
CY2023Q3 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
33765000 | |
CY2022Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
33313000 | |
CY2023Q3 | us-gaap |
Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
|
0 | |
CY2023Q3 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
|
2917000 | |
CY2023Q3 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
|
32083000 | |
CY2023Q3 | sght |
Long Term Debt Maturity After Year Three
LongTermDebtMaturityAfterYearThree
|
0 | |
CY2023Q3 | us-gaap |
Long Term Debt
LongTermDebt
|
35000000 | |
us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
900000 | ||
us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
500000 | ||
CY2023Q3 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
300000 | |
CY2022Q3 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
200000 | |
CY2023Q3 | us-gaap |
Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
|
P0Y9M18D | |
CY2023Q3 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
288000 | |
CY2022Q3 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
168000 | |
us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
869000 | ||
us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
514000 | ||
CY2023Q3 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
295000 | |
CY2022Q3 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
168000 | |
us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
885000 | ||
us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
509000 | ||
CY2023Q3 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
299000 | |
CY2023Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
662000 | |
CY2023Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
961000 | |
CY2023Q3 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
51000 | |
CY2023Q3 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
910000 | |
CY2023Q3 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
910000 | |
CY2023Q3 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
0 | |
us-gaap |
Dividends Common Stock
DividendsCommonStock
|
0 | ||
sght |
Common Stock Vote For Each Share
CommonStockVoteForEachShare
|
1 | ||
CY2023Q3 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
15632099 | |
CY2022Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
13159736 | |
us-gaap |
Sale Of Stock Description Of Transaction
SaleOfStockDescriptionOfTransaction
|
annual increases under the evergreen provision are equal to the lesser of (i) 5% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of common stock as determined by the Board, subject to certain limitations. | ||
CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
4819906 | |
CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
9.67 | |
CY2022 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y8M12D | |
CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
19463000 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
755499 | ||
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
9.79 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
704631 | ||
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
12.45 | ||
us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
165384 | ||
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
1.68 | ||
CY2023Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
4705390 | |
CY2023Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
9.57 | |
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y2M12D | ||
CY2023Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
2810000 | |
CY2023Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
2671146 | |
CY2023Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
7.79 | |
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P6Y3M18D | ||
CY2023Q3 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
2627000 | |
CY2023Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
|
4705390 | |
CY2023Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
9.57 | |
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P7Y2M12D | ||
CY2023Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
|
2810000 | |
CY2023Q3 | us-gaap |
Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
|
2100000 | |
us-gaap |
Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
|
6600000 | ||
CY2022Q3 | us-gaap |
Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
|
2400000 | |
us-gaap |
Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
|
7500000 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
6.92 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
9.58 | ||
CY2023Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
100000 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
1200000 | ||
CY2023Q3 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
17000000 | |
us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P2Y | ||
CY2022Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
47910541 | |
CY2022Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
47910541 | |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
48538517 | ||
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
48538517 | ||
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
47728845 | ||
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
47728845 | ||
CY2023Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.7982 | |
CY2023Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0404 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | ||
us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
400 | ||
CY2023Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
3856000 | |
CY2022Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
3223000 | |
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
11121000 | ||
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
9729000 | ||
CY2023Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-13035000 | |
CY2022Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-22229000 | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-44856000 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-69335000 | ||
CY2023Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
48671049 | |
CY2023Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
48671049 | |
CY2023Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.27 | |
CY2023Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.27 | |
CY2022Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.46 | |
CY2022Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.46 | |
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.92 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.92 | ||
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.45 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.45 | ||
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
6559047 | ||
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
5728939 | ||
CY2023Q3 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
20009000 | |
CY2022Q3 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
18677000 | |
us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
62305000 | ||
us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
50788000 | ||
CY2023Q3 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
2677000 | |
CY2022Q3 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
2928000 | |
us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
9105000 | ||
us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
8696000 | ||
CY2023Q3 | us-gaap |
Gross Profit
GrossProfit
|
17332000 | |
CY2022Q3 | us-gaap |
Gross Profit
GrossProfit
|
15749000 | |
us-gaap |
Gross Profit
GrossProfit
|
53200000 | ||
us-gaap |
Gross Profit
GrossProfit
|
42092000 | ||
CY2023Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
30743000 | |
CY2022Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
37594000 | |
us-gaap |
Operating Expenses
OperatingExpenses
|
99364000 | ||
us-gaap |
Operating Expenses
OperatingExpenses
|
108993000 | ||
CY2023Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-13411000 | |
CY2022Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-21845000 | |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-46164000 | ||
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-66901000 | ||
CY2023Q3 | us-gaap |
Interest Expense
InterestExpense
|
1432000 | |
CY2022Q3 | us-gaap |
Interest Expense
InterestExpense
|
1131000 | |
us-gaap |
Interest Expense
InterestExpense
|
4057000 | ||
us-gaap |
Interest Expense
InterestExpense
|
3243000 | ||
CY2023Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
1886000 | |
CY2022Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
766000 | |
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
5465000 | ||
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
846000 | ||
CY2023Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-12957000 | |
CY2022Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-22210000 | |
us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-44756000 | ||
us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-69298000 |